Ophthalmologic Approach to Chemical Burns Medication

  • Author: J Bradley Randleman, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Feb 7, 2011
 

Medication Summary

Medical therapy following irrigation in chemical injuries is geared toward promoting epithelial healing, preventing infection, preventing damage from increased IOP, and controlling pain.

Epithelial healing is promoted through aggressive lubrication, ascorbate replenishment, and judicious use of topical corticosteroids. Artificial tears and ointments are especially important with severely scarred and exposed eyes. Ascorbate, both oral and topical, aids in the synthesis of collagen fibrils. Topical steroids decrease ocular surface inflammation, facilitating new epithelial cell growth and ocular surface regeneration. The presence of epithelial defects and corneal exposure necessitates the use of prophylactic topical antibiotics to prevent infection in the already compromised eye.

Antibiotic ointments can serve the dual purpose of providing lubrication and preventing infection. Broad-spectrum antibiotic coverage is required to most effectively minimize infection.

Moderate and severe injuries often stimulate an increase in IOP due to anterior chamber inflammation and collagen fibril shortening. This condition is treated most effectively with aqueous suppressants, especially oral carbonic anhydrase inhibitors and topical beta-adrenergic blockers.

Inflamed eyes often experience ciliary spasm, which can be painful. This spasm is blocked by relatively long-acting mydriatic cycloplegics. In severe chemical injuries, oral pain medication may be required to comfort the patient.

Next

Topical antibiotics

Class Summary

Prevent ocular surface infection and effectively lubricate the eye.

Erythromycin ophthalmic

 

Macrolide broad-spectrum antibiotic.

Ciprofloxacin HCl (Ciloxan)

 

Fluoroquinolone broad-spectrum bacteriocidal antibiotic.

Previous
Next

Carbonic anhydrase inhibitors

Class Summary

Carbonic anhydrase inhibitors reduce aqueous humor production, which then reduces IOP.

Methazolamide (Neptazane)

 

Reduces aqueous humor formation by inhibiting enzyme carbonic anhydrase, which results in decreased IOP.

Acetazolamide (Diamox)

 

Decreases secretion of aqueous humor, lowering IOP.

Previous
Next

Cycloplegic mydriatics

Class Summary

Cycloplegic mydriatics reduce pain by blocking ciliary spasm, and they reduce intraocular inflammation by stabilizing the blood-aqueous barrier. Drugs from this category are chosen based on their duration of action. Intermediate-acting compounds, such as homatropine or scopolamine, are preferred to short-acting compounds, such as tropicamide, or extremely long-acting compounds, such as atropine sulfate.

Homatropine (Isopto Homatropine)

 

Blocks responses of sphincter muscle of iris and muscle of ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

Induces mydriasis in 10-30 min and cycloplegia in 30-90 min. These effects last up to 48 h.

Scopolamine ophthalmic (Isopto Hyoscine)

 

Anticholinergic agent that blocks constriction of sphincter muscle of iris and ciliary body muscle, which, in turn, results in mydriasis (dilation) and cycloplegia (paralysis of accommodation).

Previous
Next

Ascorbate

Class Summary

Critical cofactor necessary for collagen fibril synthesis. Released from the damaged cornea and the anterior chamber, and it must be replenished to promote corneal wound healing.

Ascorbic acid (Ce-vi-sol, Cecon, Cevi-Bid)

 

Water-soluble vitamin that serves as a cofactor regulating collagen synthesis.

Previous
Next

Beta-adrenergic blockers

Class Summary

Topical beta-blockers reduce aqueous humor production, which then reduces IOP.

Timolol maleate 0.25%, 0.5% (Betimol, Istalol, Timoptic, Timoptic XE)

 

May reduce elevated and normal IOP, with or without glaucoma, by reducing production of aqueous humor or by outflow.

Levobunolol hydrochloride 0.25%, 0.5% (Betagan)

 

Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production and possibly increasing outflow of aqueous humor.

Betaxolol ophthalmic (Betoptic S)

 

Selectively blocks beta 1-adrenergic receptors with little or no effect on beta 2-receptors. Reduces IOP by reducing production of aqueous humor.

Previous
Next

Topical corticosteroids

Class Summary

Steroids decrease ocular surface inflammatory response, facilitating earlier epithelial healing and regeneration. These medications must be tapered after 7-10 days because of the risk of corneal melting with prolonged use.

Prednisolone acetate 1% (Pred Forte, Econopred)

 

Decreases inflammation and corneal neovascularization.

Fluorometholone acetate 0.1% (FML, FML Forte, Flarex)

 

Decreases inflammation and corneal neovascularization.

Rimexolone 1% (Vexol)

 

Decreases inflammation and corneal neovascularization.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

J Bradley Randleman, MD  Associate Professor, Department of Ophthalmology, Section of Cornea, External Disease and Refractive Surgery, Emory University School of Medicine; Director of Cornea, External Disease and Refractive Surgery Fellowship, Emory University; Physician Member, Section of Ophthalmology, The Emory Clinic

J Bradley Randleman, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Cornea Society, and International Society of Refractive Surgery

Disclosure: Nothing to disclose.

Coauthor(s)

Alok S Bansal, MD  Resident Physician, Emory Eye Center

Alok S Bansal, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, and International Society of Refractive Surgery

Disclosure: Nothing to disclose.

Evan S Loft  MD, Clinical Assistant Professor, Department of Ophthalmology, Emory University

Evan S Loft is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Geoffrey Broocker, FACS, MD  Walthour-DeLaPerriere Professor of Ophthalmology, Department of Ophthalmology, Emory University School of MedicineChief of Service, Ophthalmology, Grady Memorial Hospital

Geoffrey Broocker, FACS, MD is a member of the following medical societies: American College of Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Fernando H Murillo-Lopez, MD  Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD  Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD  Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Merle H, Gerard M, Schrage N. [Ocular burns]. J Fr Ophtalmol. Sep 2008;31(7):723-34. [Medline].

  2. Hodge C, Lawless M. Ocular emergencies. Aust Fam Physician. Jul 2008;37(7):506-9. [Medline].

  3. Spector J, Fernandez WG. Chemical, thermal, and biological ocular exposures. Emerg Med Clin North Am. Feb 2008;26(1):125-36, vii. [Medline].

  4. Pfister DA, Pfister RR. Acid injuries of the eye. Fundamentals of Cornea and External Disease. Cornea. Vol 2. 2005:1277-84.

  5. Pfister RR, Pfister DA. Alkali injuries of the eye. In: Fundamentals of Cornea and External Disease. Cornea. Vol 2. 2005:1285-93.

  6. Xiang H, Stallones L, Chen G, Smith GA. Work-related eye injuries treated in hospital emergency departments in the US. Am J Ind Med. Jul 2005;48(1):57-62. [Medline].

  7. Morgan SJ. Chemical burns of the eye: causes and management. Br J Ophthalmol. Nov 1987;71(11):854-7. [Medline].

  8. Klein R, Lobes LA Jr. Ocular alkali burns in a large urban area. Ann Ophthalmol. Oct 1976;8(10):1185-9. [Medline].

  9. Wagoner MD, Kenyon KR. Chemical injuries of the eye. Clinical Practice. In: Albert, Jakobiec, eds. Principles and Practice of Ophthalmology. Vol 2. 2000:943-59.

  10. Kheirkhah A, Johnson DA, Paranjpe DR, Raju VK, Casas V, Tseng SC. Temporary sutureless amniotic membrane patch for acute alkaline burns. Arch Ophthalmol. Aug 2008;126(8):1059-66. [Medline].

  11. Tandon R, Gupta N, Kalaivani M, et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. Br J Ophthalmol. Feb 2011;95(2):199-204. [Medline].

  12. Brodovsky SC, McCarty CA, Snibson G, et al. Management of alkali burns : an 11-year retrospective review. Ophthalmology. Oct 2000;107(10):1829-35. [Medline].

  13. Kheirkhah A, Johnson DA, Paranjpe DR, Raju VK, Casas V, Tseng SC. Temporary sutureless amniotic membrane patch for acute alkaline burns. Arch Ophthalmol. Aug 2008;126(8):1059-66. [Medline].

  14. Kawashima M, Kawakita T, Satake Y, Higa K, Shimazaki J. Phenotypic study after cultivated limbal epithelial transplantation for limbal stem cell deficiency. Arch Ophthalmol. Oct 2007;125(10):1337-44. [Medline].

  15. Tuft SJ, Shortt AJ. Surgical rehabilitation following severe ocular burns. Eye. Jan 23 2009;[Medline].

  16. Dua HS, King AJ, Joseph A. A new classification of ocular surface burns. Br J Ophthalmol. Nov 2001;85(11):1379-83. [Medline].

Previous
Next
 
Alkali burn. Note the severe conjunctival reaction and stromal opacification blurring iris details inferiorly.
Severe chemical injury with early corneal neovascularization.
Complete cicatrization of the corneal surface following chemical injury.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.